SASP gene delivery: A novel antibacterial approach

  • Fairhead H.
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Antibiotic resistance is a global problem, and with bacteria having developed resistance to all approved antibacterial agents there is a growing need for innovative solutions. Phico Therapeutics has developed a new class of antibacterial agent, a platform technology called SASPject. SASPject comprises modified, disabled bacterial viruses (bacteriophages) injecting a gene encoding an antibacterial protein, SASP, into target bacteria. SASP, or Small, Acid-soluble Spore Protein(s), inactivate bacterial DNA in a non-sequence-specific manner so their activity is unaffected by DNA mutations. Selected pathogens can be targeted, avoiding the normal flora. A Staphylococcus oureus-targeted SASPject, PT1.2, developed for the nasal : decolonization of S. aureus, including methicillin-resistant (MRSA) strains, is expected to complete phase I in 2009. SASPject PT1.2 shows good in vitro activity against a wide range of diverse clinical S. aureus isolates, including MRSA strains. A systemic SASPject PT1.2, and SASPjects targeted against Clostridium difficile and multidrug-resistant Gram-negative organisms are in development. The SASPject technology could represent a new paradigm in antibacterial therapeutics. Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

There are no full text links


  • Fairhead H.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free